Stock AnalizRegencell Bioscience Holdings Ltd RGC
Medicinal Chemicals and Botanical Products · IPO 2021 · data as of November 13, 2026
Regencell Bioscience Holdings Ltd (RGC) is a healthcare company listed in the US with a market value of about $2.4B.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -48%.
Score: 0.4 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 8 years
| Fiscal year | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Net income | -$12M | -$4M | -$4M | -$6M | -$7M | -$1M | -$812371 | -$390990 |
| Free cash flow | — | -$3M | -$4M | -$5M | -$6M | — | -$844410 | — |
| EPS (diluted) | $-0.02 | $-0.01 | $-0.01 | $-0.01 | $-0.01 | $-0.00 | $-0.00 | $-0.00 |
| Net margin | — | — | — | — | — | — | — | — |
| ROIC | -67.9% | -55.1% | -45.1% | -39.7% | -33.7% | — | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does Regencell Bioscience Holdings pay a dividend?
Not currently.
Is Regencell Bioscience Holdings a good stock to buy?
We do not give buy or sell advice. Regencell Bioscience Holdings scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.